AUTHORS
Claudia Morris, MD, Noor Alzraikat, MD2, Maurice Leary3, Bryant Azohoh4, Andrew Campbell, MD5, Robert Nickel, MD, MSc6, Deepika Darbari, MD7, Zaina Inam, MD8, Joshua Chandler, PhD9, Frank Harris10, Kenneth McKinley, MD11, Suvankar Majumdar, MD12
AFFILIATIONS
1 Emory University, Atlanta, United States
2 Emory University, Atlanta, United States
3 Children's National Hospital, Washington, United States
4 Children's National Hospital, Washington, United States
5 Children's National Hospital, Washington, United States
6 Children's National Hospital, Washington, United States
7 Children's National Hospital, Washington, United States
8 Children's National Hospital, Washington, United States
9 Emory University, Atlanta, United States
10 Emory University, Atlanta, United States
11 Children's National Hospital, Washington, United States
12 Children's National Hospital, Washington, United States
ABSTRACT
Introduction
Acute pain is the leading cause of emergency department (ED) visits and hospitalization in patients with sickle cell disease (SCD), yet no FDA-approved therapies are available, and treatment remains largely supportive. Arginine is the obligate substrate for nitric oxide (NO) synthesis. NO, a potent vasodilator, is depleted in SCD, contributing to endothelial dysfunction and vasoconstriction. Citrulline, an arginine prodrug, bypasses metabolism by arginase compared to arginine supplementation, which may more efficiently increase systemic arginine availability and restore NO bioavailability. Previous randomized clinical trials have demonstrated that intravenous arginine is safe and reduces pain scores, opioid requirements, and hospital length of stay in children hospitalized with SCD-related acute pain, supporting investigation of citrulline as an alternative strategy to augment arginine and NO bioavailability. We aimed to characterize the pharmacokinetic and pharmacodynamic profile of intravenous L-citrulline during acute SCD-pain in the first 15 enrolled participants.
Methods
We conducted a single-center, phase 2, randomized, double-blind, placebo-controlled trial of intravenous L-citrulline in children and young adults with SCD aged 4–21 years hospitalized with acute pain. Participants were randomized 1:1:1 to receive low-dose L-citrulline (25 mg/kg bolus + 9 mg/kg/hr infusion), high-dose L-citrulline (50 mg/kg bolus + 9 mg/kg/hr infusion), or placebo over 16 hours. Plasma citrulline and arginine concentrations were measured at baseline, 10 minutes after the intravenous bolus, and at 3 or 6, and 16 hours to characterize pharmacokinetic and pharmacodynamic profiles. Analyses were performed blinded to treatment assignment. To maintain blinding, all groups were combined for analysis.
Results
Fifteen participants were enrolled (mean age 13.8 ± 4.4 years; 60% male, 66.7% receiving hydroxyurea). Genotype distribution was 80% HbSS, 13.3% HbSC, and 6.7% HbSβ⁺thalassemia. Mean baseline plasma citrulline concentration was and increased significantly (p= 0.0062) following intravenous administration, reaching its maximum at 10 minutes before declining at subsequent timepoints. Mean baseline plasma L-arginine concentration was 53.4 ± 28.5 μM and significantly increased by 3 hours (p=0.0047). Peak citrulline and peak arginine concentrations demonstrated a moderate positive correlation (r=0.56), although this did not reach statistical significance, likely due to the small sample size. (p=0.19). At 16 hours, mean plasma citrulline and L-arginine concentrations were 195.7 ± 270.4 μM and 105.0 ± 75.0 μM, respectively.
Conclusion
Intravenous L-citrulline produced a rapid increase in plasma citrulline followed by a subsequent increase in plasma L-arginine concentration, consistent with renal conversion of citrulline to arginine. These findings confirm that citrulline therapy improves arginine bioavailability which may contribute mechanistically to analgesic effects of L-citrulline. These data support the need for further evaluation of citrulline as a therapeutic strategy for acute SCD pain.
DISCLOSURES
Claudia Morris, MD: TRILITY - Consultancy (Includes expert testimony); CSL Behring, F. Hoffmann-La Roche LTD - Consultancy (Includes expert testimony); octapharma - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony)